Neuphoria Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Sep 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 18, 2026
NEUP$2.69-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(13,451,931) | $(369,632) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||
| Share-based compensation | 351,600 | 163,772 |
| Goodwill impairment | 5,362,000 | - |
| Depreciation and amortization expense | 662,955 | 662,890 |
| Non-cash rent expense | 102,612 | 114,363 |
| Change in fair value of accompanying warrant liability | (1,730,321) | (956,340) |
| Change in fair value of contingent consideration | (198,888) | 716,654 |
| Effect of foreign currency remeasurement | 603,313 | 242,348 |
| Changes in assets and liabilities: | ||
| Accounts receivable, non-trade | (801,483) | 114,936 |
| Prepaid expenses | 350,421 | (453,058) |
| Accounts payable | (768,785) | (917,663) |
| Accrued expenses and other current liabilities | (2,579,080) | 1,486,656 |
| Operating lease liabilities | (116,314) | (123,304) |
| Deferred tax liability | (139,173) | (468,427) |
| Contingent consideration | - | (133,080) |
| Other non-current liabilities | - | (2,886) |
| Net cash (used in) provided by operating activities | (12,353,074) | 77,229 |
| Cash flows from financing activities: | ||
| Proceeds from the sale of equity, net of issuance costs of $0.6 million | 17,915,883 | - |
| Proceeds from the sale of equity, net of subscriptions receivable of $0.1 million and issuance costs of $0.1 million | - | 1,528,276 |
| Net cash provided by financing activities | 17,915,883 | 1,528,276 |
| Effect of exchange rate on changes in cash, cash equivalents, and restricted cash | 14,032 | (3,750) |
| Net increase in cash, cash equivalents, and restricted cash | 5,576,841 | 1,601,755 |
| Cash, cash equivalents, and restricted cash, beginning of period | 14,288,690 | 12,686,935 |
| Cash, cash equivalents, and restricted cash, end of period | $19,865,531 | $14,288,690 |
| Reconciliation of cash, cash equivalents, and restricted cash: | ||
| Cash and cash equivalents | $19,865,531 | $14,210,745 |
| Restricted cash | - | 77,945 |
| Total cash, cash equivalents, and restricted cash | $19,865,531 | $14,288,690 |
| Supplemental cash flow data: | ||
| Cash paid for interest expense | $3,857 | $17,433 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.